Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework

Journal of Otolaryngology - Head & Neck Surgery

Davide Cattano¹  Martin J. Citardi²  Syed H. S. Naqvi²  Mark I. Knackstedt²  Ron J. Karni²  Luis Ostrosky-Zeichner³ 

[1] Department of Anesthesiology, McGovern Medical School, The University of Texas Health Science Center at Houston, 77030, Houston, TX, USA;Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin Street, MSB 5.036, 77030, Houston, TX, USA;Division of Infectious Diseases, Department of Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, 77030, Houston, TX, USA;

关键词: Povidone-iodine;    Betadine;    SARS-CoV-2;    Prophylaxis;    COVID-19;    Upper Aerodigestive tract;   

DOI  :  10.1186/s40463-020-00474-x

来源: Springer

【 摘 要 】

BackgroundThe COVID-19 pandemic has raised concerns of inadvertent SARS-CoV-2 transmission to healthcare workers during routine procedures of the aerodigestive tract in asymptomatic COVID-19 patients. Current efforts to mitigate this risk focus on Personal Protective Equipment, including high-efficiency filtration as well as other measures.Because the reservoir for SARS-CoV-2 shedding is in the nasopharynx and nasal and oral cavities, the application of viricidal agents to these surfaces may reduce virus burden. Numerous studies have confirmed that povidone-iodine inactivates many common respiratory viruses, including SARS-CoV-1. Povidone-iodine also has good profile for mucosal tolerance. Thus, we propose a prophylactic treatment protocol for the application of topical povidone-iodine to the upper aerodigestive tract.ConclusionSuch an approach represents a low-cost, low-morbidity measure that may reduce the risks associated with aerosol-generating procedures performed commonly in otorhinolaryngology operating rooms.Graphical abstract

【 授权许可】

CC BY